FDA Approved New Potency Assay for Ryoncil
The federal agency has cleared a new testing method to ensure quality for the cell therapy used in children.
Updated on Sept. 24, 2026 in Biotech
Live Poll
Do you believe recent company-specific regulatory approvals make now a good time to invest?
The U.S. FDA has approved the T-cell Proliferation Inhibition BioAssay for Ryoncil, an MSC therapy for steroid-refractory acute graft versus host disease. The new testing process is designed to improve the release and stability monitoring of product batches.
Why it matters
The updated testing protocol allows for better sensitivity when detecting potency changes during manufacturing scale-up or facility shifts. This enhancement helps ensure the consistency and quality of the therapy as the company broadens its reach.
The new T-cell Proliferation Inhibition BioAssay will function alongside existing assays to provide granular sensitivity for product quality checks. It specifically targets detection of potency variations during manufacturing scale-up.
The players
U.S. FDA
The federal agency responsible for protecting public health by ensuring the safety and efficacy of medical products and biologics.
Mesoblast
A biotechnology company that specializes in the development of innovative cellular medicines for the treatment of inflammatory diseases.
The details
Ryoncil is an FDA-approved mesenchymal stem cell (MSC) therapy indicated for pediatric patients aged 2 months and older suffering from steroid-refractory acute graft versus host disease. Mesoblast currently intends to leverage its platform to expand into other inflammatory conditions and advance additional therapies like rexlemestrocel-L.
Timeline
The FDA approved the new Ryoncil potency assay on September 24, 2026.
The Tech Race
The integration of advanced bio-assays reflects a broader industry shift toward rigorous automation and sensitivity in biologics manufacturing. These improvements position Mesoblast to better navigate complex regulatory requirements as it scales its platform against competitors.
This regulatory update ensures that patients receiving Ryoncil benefit from enhanced manufacturing quality and consistent potency standards. It marks a step toward more stable production of specialized cell therapies for pediatric patients.
The takeaway
This assay approval provides a critical framework for maintaining product integrity during commercial scale-up processes. Biotech firms can implement such validated testing methods to demonstrate continued safety and efficacy as their product pipelines evolve.
Further reading
For more background on developments in cellular medicine, visit the Biotech section.
Live Poll
Do you believe recent company-specific regulatory approvals make now a good time to invest?
